Intervention: Pharmacological intervention

This refers to the drug, therapy, or factor being studied in a clinical trial or observational study. Examples include antiviral agents monoclonal antibodies, corticosteroids, vaccines and other pharmacological agents

Colaneri 2

Italy
|
2021-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Sotrovimab
  • Molnupiravir
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab
  • Bamlanivimab/ Etesevimab

Kautsch

Poland
|
2020-2023
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir

Bernal

Spain
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Remdesivir
  • Steroids
  • Dexamethasone

Entrenas-Castillo

Spain
|
2020-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Steroids
  • Vitamin D

Patel

United Kingdom
|
2021-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Adolescents (12-17 years)
  • Community
  • Primary care
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Monoclonal antibodies
  • Nirmatrelvir/Ritonavir
  • Sotrovimab
  • Molnupiravir

Drysdale 2

Belgium
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Adolescents (12-17 years)
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab

De Vito

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Molnupiravir

Basoulis

Greece
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir

COCOPREV

France
|
2021-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Hospital
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab
  • Tixagevimab/Cilgavimab
  • Casirivimab/Imdevimab

Patel 2

United Kingdom
|
2022-2022
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Fragile population
  • Adolescents (12-17 years)
  • Emergency department
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Sotrovimab

Ismail

Greece Denmark Germany
|
2020-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Statins

Rinaldi

Italy
|
2022-2022
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Fragile population
  • Immunocompromised host
  • Outpatient clinic
  • SARS-CoV-2
  • Acute COVID-19
  • Pharmacological intervention
  • Antivirals
  • Nirmatrelvir/Ritonavir
  • Remdesivir
  • Molnupiravir